secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2025-07-21T23:59:59+00:00
Accession:  0001723128-25-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns
------------------------------------------------------------------------------

- Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.
- Adjusted EBITDA $180M-$185M (+13% YoY); gross leverage 3.8x, net leverage 3.7x.
- Director Emily Peterson Alva resigned July 16 after Amneal Group ownership dropped below majority of Class A common stock.
- Brekiya autoinjector approved for migraine/cluster headache; CREXONT uptake strong; biosimilar to XOLAIR BLA expected Q4 2025.
- Full year 2025 guidance expected to be met or exceeded based on year-to-date performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/0001723128-25-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000033/amrx-20250716.htm
  HTML page:      https://secwatch.observer/filing/0001723128-25-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer